((自动化翻译由路透提供，请见免责声明 ))
路透社哥本哈根11月26日 - 丹麦减肥药生产商诺和诺德 的股价周二上涨了1.3%，因为美国总统乔-拜登提议扩大数百万医疗保险和医疗补助计划（Medicare和Medicaid）抗肥胖药物的 (link)。
"诺和诺德公司在一份评论该提议的声明中说："这对患者来说是向前迈出的重要一步。
现行的医疗保险和医疗补助政府健康保险计划规定，Mounjaro、Ozempic 和 Wegovy 等药物可用于治疗糖尿病等特定病症，但不能单独用于治疗肥胖症。
白宫在一份声明中说，该提案可将减肥药的自付费用降低高达95%，从而扩大数百万美国人的用药范围。
Nordnet分析师佩尔-汉森（Per Hansen）说，诺和诺德的股价走势 (link)，美国同行礼来 也在盘前交易中上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.